Endothelial dysfunction is an early step to the progression of cardiovascular diseases in
diabetes. Apart from their anti-diabetic action, DPP-4 (dipeptidyl peptidase-4) inhibitors also …

Background Vildagliptin, a DPP-4 inhibitor widely used for the treatment of type 2 diabetes
mellitus (T2DM), shows beneficial effects on endothelial function. This study aims to …

Hyperglycemia or high blood sugar is one of the major pathological characteristics of
diabetes. The endothelium is the inner layer of the vascular wall and is directly exposed to …

Dipeptidyl peptidase-4 inhibitors are known to lower glucose levels and are also beneficial
in the management of cardiovascular disease. Here, we investigated whether a dipeptidyl …

Background: Several trials have reported that dipeptidyl peptidase-4 (DPP-4) inhibitors are
used to improve endothelial function in addition to treating type 2 diabetes (T2DM). The …

Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors,
antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type …

Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors may have protective effects
in the early stage of atherosclerosis in patients with type 2 diabetes, although similar effects …

Summary Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel antidiabetic agents with
possible vascular protection effects. Endothelial dysfunction is an initiation step in …

Aim Several recent reports have revealed that dipeptidyl peptidase (DPP)-4 inhibitors have
suppressive effects on atherosclerosis in apolipoprotein E-null (Apoe−/−) mice. It remains to …

OBJECTIVE To investigate whether the dipeptidyl peptidase-4 inhibitor vildagliptin improves
endothelium-dependent vasodilatation in patients with type 2 diabetes. RESEARCH …